LANTHEUS HOLDINGS INC (LNTH)
Health Care · medical imaging & diagnostics · NASDAQ
Lantheus is a specialist in diagnostic imaging agents and radiopharmaceuticals that help clinicians visualize cardiovascular conditions and oncological disease states.
What LANTHEUS HOLDINGS INC does
Lantheus Holdings is a medical imaging company that develops, manufactures, and commercializes innovative diagnostic and therapeutic products. The company’s portfolio includes contrast agents for diagnostic ultrasound imaging and specialized radiopharmaceuticals for use in nuclear medicine. Their products are essential tools for clinicians to diagnose cardiovascular diseases and certain types of cancers.
Themes: diagnostic imaging, nuclear medicine, oncology diagnostics, cardiology diagnostics
Fundamentals
- Price$99.97 as of 2026-08-21 close
- Market cap$6.5B as of 2026-08-21
- 1-year return+69.0% 2025-08-21 close $59.16 → 2026-08-21 close $99.97
- P/E23.92 as of 2026-08-24
- Net margin+17.7% as of 2026-08-24
- Gross margin+61.0% as of 2026-08-24
- ROE+23.3% as of 2026-08-24
- Debt / equity0.44 as of 2026-08-24
- Revenue growth (YoY)+2.4% as of 2026-08-24
- Revenue CAGR (3y)+18.1% SEC XBRL
- Beta-0.04 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How LNTH compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
LNTH is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
38.8 #1441 of 1,704 scored · #213 of 240 in Health Care
Setup 44th: day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move; trend 43rd: a "golden cross" — its 50-day average is above its 200-day; weakest is catalysts 22nd: the analyst consensus rating has softened toward "sell" since the prior reading.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which LNTH reported a dividend payment is FY2013, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2013 ratio would not describe LNTH today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2013) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How LANTHEUS HOLDINGS INC looks technically
LANTHEUS HOLDINGS INC (LNTH) is trading 22.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 129 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 16 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 22.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +22.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $103.98 | $103.98 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $81.43 | $81.43 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 21 calendar days ago — the swings before that are what the structure reading is measured on | 21 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 98.81. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 129 trading days ago — a "golden cross", a bullish long-term signal | 129 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 12.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30) | 42.5 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($99.97 to $102.05) — its "stochastic" reading is 0 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 0.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 35 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $111.86 | $111.86 |
|---|---|---|
| From the 52-week high | it is 10.6% below its 52-week high (its highest price of the past year) | -10.6% |
| Above the 52-week low | it is 101.3% above its 52-week low (its lowest price of the past year) | +101.3% |
| Below the 52-week high | it is 10.6% below its highest point of the past year | 10.6% |
| Since a 20-day breakout | it made a new 20-day low about 16 trading days ago | 16 sessions |
| Since a 55-day breakout | it made a new 55-day high about 38 trading days ago | 38 sessions |
| All-time high | its highest closing price on record is $126.89 (set on 2024-07-16) | $126.89 |
| Given back of the 52-week move | over the past year its closes ranged ($50.11 to $110.94), and it has given back roughly a quarter of its rise from last year’s low — 18% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $71.40 to $73.35. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 18.0% |
| From the all-time high | it is 21.2% below its all-time high | -21.2% |
| Nearest price level | it is sitting right on a resistance level at $100.31 — a price it turned at twice since 2025-01-28, most recently on 2026-07-07. Since 2024-08-21 it has 10 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.3% |
| All-time low | its lowest closing price on record is $1.76 (set on 2016-02-10) | $1.76 |
| Above the all-time low | it is 5580.1% above its all-time low | +5,580% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 0th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.66 between its high and its low — about 1.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.66 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $97.78 and $104.55 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $97.78 – $101.16 – $104.55 |
| Typical daily range (% of price) | its price moves about 1.7% in a typical session — among the calmest in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 1.7% |
| Stretch from the 200-day average | it is trading 11.2 daily ranges above its 200-day average price (22.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 11.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.63× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.2% since the prior reading | -0.2% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.18 toward sell |
Candlestick patterns
2
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a bearish engulfing | 3 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 3 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Open gap | it gapped 3.1% above the previous close 14 sessions ago and has not traded back through the level it left behind at 99.64 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.1% |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -0.51% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 9.7 percentage points (the stock lost 7.4% while the market gained 2.3%) | -9.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 2.7 percentage points (the stock gained 5.8% while the market gained 3.1%) | +2.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 24.3 percentage points (the stock gained 35.3% while the market gained 11.1%) | +24.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 48.5 percentage points (the stock gained 69.0% while the market gained 20.5%) | +48.5% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 9.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 11% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $90.08 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +11.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $100.67 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -0.7% |
Price levels it has turned at before
LNTH last closed at $99.97 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $100.31 | Resistance | 0.3% above the last close | turned there twice · 2025-01-28 to 2026-07-07 |
| $97.80 | Support | 2.2% below the last close | turned there five times · 2024-09-11 to 2026-07-31 |
| $104.29 | Resistance | 4.3% above the last close | turned there three times · 2024-10-29 to 2026-05-22 |
| $91.50 | Support | 8.5% below the last close | turned there twice · 2024-11-26 to 2026-05-19 |
| $109.19 | Resistance | 9.2% above the last close | turned there twice · 2025-05-02 to 2026-07-20 |
| $87.56 | Support | 12.4% below the last close | turned there four times · 2024-12-03 to 2025-01-13 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $98.81.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · beating the market · Least volatile (2% or less typical daily range) · Stretched far above its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · breakout · bollinger bands
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.55 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$107.04 range $102.50 – $115.00; median $105.20
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for LNTH
- Consensus EPS estimate$1.35 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant reliance on a limited number of products and key suppliers.","Risks associated with regulatory approvals, clinical trial success, and changing healthcare reimbursement policies.","Potential for intensive competition and intellectual property challenges."]
What changed in the latest 10-Q
AI-assisted comparison of LNTH's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Added forward-looking statement indicator word 'ensuring' to the list of identifying words (filed 2026-05-07)
- Added reference to PYLARIFY TruVu as new formulation with FDA approval on March 6, 2026 (filed 2026-05-07)
- Added statement about ability to obtain FDA approval for each PMF to manufacture PYLARIFY TruVu (filed 2026-05-07)
- Added PYLARIFY TruVu and LNTH-2501 to list of products requiring PET scanner availability (filed 2026-05-07)
- Added 'Lantheus Biosciences' as acquired entity alongside Evergreen in integration discussion (filed 2026-05-07)
- Added 'Neuraceq' as asset usable in clinical development partnerships (filed 2026-05-07)
- Added reference to PNT2003 receiving FDA tentative approval in March 2026 (filed 2026-05-07)
- Added language about 'newly approved products' and 'investigational assets for which FDA approval has been obtained or is anticipated to be obtained this year' (filed 2026-05-07)
- Added reference to 'recent turnover' in leadership (filed 2026-05-07)
- Added filing date of Form 10-K as February 26, 2026 with specific accession reference (filed 2026-05-07)
- Removed:
- Removed reference to 'reimbursement' for established commercial products from forward-looking statements (filed 2025-11-06)
- Removed 'Life Molecular' from list of acquisitions to integrate (filed 2026-05-07)
- Removed entire section (vii) regarding SPECT business sale to SHINE Technologies (filed 2026-05-07)
- Removed reference to 'single-photon emission computerized tomography (SPECT) business' (filed 2026-05-07)
- Removed language describing LNTH-2501 as 'may be used' and 'gastroenteropancreatic neuroendocrine tumors' (filed 2026-05-07)
- Removed reference to obtaining 'manufacturing' approval for new PSMA formulation (filed 2026-05-07)
- Removed reference to 'HCPs' (healthcare professionals) in context of equipment availability (filed 2026-05-07)
- Removed language 'and approval for PNT2003' as separate item requirement (filed 2026-05-07)
- Removed reference to Form 10-K year ended December 31, 2024 (filed 2026-05-07)
- Reworded:
- Changed 'from such acquisitions' to 'related to such acquisitions' regarding future revenues and expenses (filed 2026-05-07)
- Changed 'continued market expansion and penetration' to 'continued market expansion, penetration and reimbursement' (filed 2026-05-07)
- Restructured item (ii) from discussing ability to obtain FDA approval for new formulation to discussing ability to complete technology transfer for already-approved PYLARIFY TruVu (filed 2026-05-07)
- Changed 'by healthcare professionals' to 'by customers of our products' regarding equipment availability (filed 2026-05-07)
- Reordered and consolidated manufacturing and third-party manufacturing items (items ii and iii became items iv and v respectively) (filed 2026-05-07)
- Consolidated clinical partnership language to include Neuraceq alongside MK-6240 and NAV-4694 (filed 2026-05-07)
- Changed PNT2003 language from seeking approval to already having 'FDA tentative approval in March 2026' (filed 2026-05-07)
- Removed date specificity from integration acquisitions discussion (filed 2026-05-07)
- Changed Form 10-K reference from general to specific filing date and SEC accession information (filed 2026-05-07)
- Notes:
- Text appears truncated at end of both versions; complete comparison of 'Available Information' section may not be fully assessable
- Some changes reflect regulatory developments (FDA approvals, tentative approvals) that occurred between filing dates rather than disclosure choice changes
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for LNTH — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 4 matched disclosures for LNTH from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding LNTH as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 15,777,895
- Reported value $1,196,753,315
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
LNTH had 6,309,139 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
LNTH had 9.67% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.56 days to cover at the same settlement.
- Reported short interest (shares) 6,309,139
- Short interest (% of shares outstanding) 9.67%
- Prior settlement (shares) 6,401,705
- Reported change -1.45%
- Days to cover (reported) 6.56
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- GE Healthcare (GEHC)
- Bracco Imaging
- Curium
- Cardinal Health (CAH)
- Telix Pharmaceuticals (TLX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare LNTH vs…
Frequently asked questions
What does LANTHEUS HOLDINGS INC (LNTH) do?
Lantheus Holdings is a medical imaging company that develops, manufactures, and commercializes innovative diagnostic and therapeutic products. The company’s portfolio includes contrast agents for diagnostic ultrasound imaging and specialized radiopharmaceuticals for use in nuclear medicine. Their products are essential tools for clinicians to diagnose cardiovascular diseases and certain types of cancers.
What sector is LANTHEUS HOLDINGS INC (LNTH) in?
LANTHEUS HOLDINGS INC (LNTH) is classified in the Health Care sector. Its industry is medical imaging & diagnostics. It trades on NASDAQ.
Who are LANTHEUS HOLDINGS INC's (LNTH) competitors?
Notable peers of LANTHEUS HOLDINGS INC (LNTH) include GE Healthcare, Bracco Imaging, Curium, Cardinal Health and Telix Pharmaceuticals. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in LNTH?
Yes — we hold 4 matched STOCK Act disclosures for LNTH from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is LANTHEUS HOLDINGS INC (LNTH) overbought or oversold right now?
LANTHEUS HOLDINGS INC (LNTH) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 43, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LNTH come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.